Close Menu

LA JOLLA, Calif.--Genomics company Sequana Therapeutics here has earned a milestone payment from Glaxo Wellcome in recognition of its success in identifying certain regions of DNA that contain genes associated with noninsulin-dependent diabetes. "This is an important step toward finding the genes responsible for diabetes," commented Callum Bell, Sequana's project leader for diabetes research. "Combining Sequana's high-technology gene discovery platform with Glaxo Wellcome's expertise in the field of diabetes has permitted very rapid progress," he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.